甲状腺激素受体
甲状腺激素受体α
甲状腺激素受体β
化学
核受体
受体
激素受体
兴奋剂
配体(生物化学)
促甲状腺激素释放激素受体
甲状腺
激素
辅活化剂
雌激素相关受体γ
生物化学
立体化学
内分泌学
内科学
生物
转录因子
医学
基因
乳腺癌
癌症
作者
Sabine Borngraeber,Mary-Jane Budny,Grazia Chiellini,Suzana Telles da Cunha Lima,Marie Togashi,Paul Webb,John D. Baxter,Thomas S. Scanlan,Robert J. Fletterick
标识
DOI:10.1073/pnas.2136689100
摘要
Selective therapeutics for nuclear receptors would revolutionize treatment for endocrine disease. Specific control of nuclear receptor activity is challenging because the internal cavities that bind hormones can be virtually identical. Only one highly selective hormone analog is known for the thyroid receptor, GC-24, an agonist for human thyroid hormone receptor β. The compound differs from natural hormone in benzyl, substituting for an iodine atom in the 3′ position. The benzyl is too large to fit into the enclosed pocket of the receptor. The crystal structure of human thyroid hormone receptor β at 2.8-Å resolution with GC-24 bound explains its agonist activity and unique isoform specificity. The benzyl of GC-24 is accommodated through shifts of 3–4 Å in two helices. These helices are required for binding hormone and positioning the critical helix 12 at the C terminus. Despite these changes, the complex associates with coactivator as tightly as human thyroid hormone receptor bound to thyroid hormone and is fully active. Our data suggest that increased specificity of ligand recognition derives from creating a new hydrophobic cluster with ligand and protein components.
科研通智能强力驱动
Strongly Powered by AbleSci AI